Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy

Effectiveness of Enhanced Recovery After Surgery (ERAS) on Postoperative Recovery After Minimally Invasive Gastrectomy: A Multi-center Open-labeled Randomized Controlled Study

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This prospective, randomized, open-label, multicenter study is designed to evaluate the impact of an enhanced recovery after surgery (ERAS) protocol on the rate of meeting discharge criteria in patients undergoing minimally-invasive gastrectomy for gastric cancer. We hypothesize that implementation of our ERAS protocol will significantly increase the proportion of patients who meet standardized discharge criteria following minimally-invasive gastrectomy.

Who May Be Eligible (Plain English)

Who May Qualify: - Adults aged ≥19 years scheduled to undergo elective laparoscopic or robotic gastrectomy for gastric cancer - American Society of Anesthesiologists physical status classification I to III - Ability to provide written willing to sign a consent form, demonstrate understanding of the study protocol, and complete patient-reported outcome measures appropriately Who Should NOT Join This Trial: - Requirement for resection of organs other than the stomach during surgery (except for cholecystectomy) - History of upper abdominal surgery (except for cholecystectomy) - Known hypersensitivity to fentanyl, ropivacaine, acetaminophen, or non-steroidal anti-inflammatory drugs - Determined by the investigator or study personnel to be otherwise unsuitable for participation in the study Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Adults aged ≥19 years scheduled to undergo elective laparoscopic or robotic gastrectomy for gastric cancer * American Society of Anesthesiologists physical status classification I to III * Ability to provide written informed consent, demonstrate understanding of the study protocol, and complete patient-reported outcome measures appropriately Exclusion Criteria: * Requirement for resection of organs other than the stomach during surgery (except for cholecystectomy) * History of upper abdominal surgery (except for cholecystectomy) * Known hypersensitivity to fentanyl, ropivacaine, acetaminophen, or non-steroidal anti-inflammatory drugs * Determined by the investigator or study personnel to be otherwise unsuitable for participation in the study

Treatments Being Tested

PROCEDURE

ERAS protocol

The ERAS protocol includes pre-admission patient education through audiovisual materials; reduction of perioperative fasting duration with preoperative carbohydrate loading and early postoperative oral intake; multimodal prophylaxis for postoperative nausea and vomiting; early removal of surgical drains and intravenous lines; early mobilization; and multimodal analgesia aimed at minimizing postoperative opioid use. The detailed protocol used in this study has been published previously \[https://doi.org/10.5230/jgc.2025.25.e27\].

Locations (10)

Pusan National University Hospital
Busan, South Korea
Dongsan Hospital, Keimyung University School of Medicine
Daegu, South Korea
Chungnam National University Hospital
Daejeon, South Korea
National Cancer Center
Goyang, South Korea
Seoul National University Bundang Hospital
Seongnam, South Korea
Seoul National University Hospital
Seoul, South Korea
Seoul St. Mary's Hospital
Seoul, South Korea
Severance hospital
Seoul, South Korea
SMG-SNU Boramae Medical Center,
Seoul, South Korea
Ajou University School of Medicine
Suwon, South Korea